



Assessment of pulmonary tissue responses in pigs challenged with PRRSV Lena strain shows better protection after immunization with field than vaccine strains

Thibaut Larcher, Christelle Fablet, Patricia Renson, Déborah Menard, Caroline Hervet, Georges Saade, Catherine Belloc, Olivier Bourry, François Meurens

► To cite this version:

Thibaut Larcher, Christelle Fablet, Patricia Renson, Déborah Menard, Caroline Hervet, et al.. Assessment of pulmonary tissue responses in pigs challenged with PRRSV Lena strain shows better protection after immunization with field than vaccine strains. *Veterinary Microbiology*, 2019, 230, pp.249-259. 10.1016/j.vetmic.2019.01.022 . hal-02061157

HAL Id: hal-02061157

<https://hal.science/hal-02061157>

Submitted on 22 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Assessment of pulmonary tissue responses in pigs challenged with PRRSV Lena strain shows better protection after immunization with field than vaccine strains

Thibaut Larcher¹, Christelle Fablet^{2,3}, Patricia Renson^{2,3,4}, Déborah Ménard⁵, Caroline Hervet⁵, Georges Saade⁵, Catherine Belloc⁵, Olivier Bourry^{2,3§}, and François Meurens^{5§*}

¹PAnTher, INRA, Oniris, Université Bretagne Loire, 44307, Nantes, France

²Agence Nationale de Sécurité Sanitaire Alimentation Environnement Travail (Anses), BP 53, 22440 Ploufragan, France

³Université Bretagne Loire, 44307, Nantes, France

⁴IFIP-Institut du porc, 5 Rue Lespagnol, 75020 Paris, France

⁵BIOEPAR, INRA, Oniris, Université Bretagne Loire, 44307, Nantes, France

[§]Contributed equally to this work

^{*}Corresponding author: Email: francois.meurens@oniris-nantes.fr; Phone: +33 240 68 77 02; Fax: +33 240 68 28 02.

Short Running Title: Pulmonary response to Lena PRRSV strain in immunized pig

Keywords: PRRSV; lung; immune response; chemokine; chemokine receptor; tissue scoring; genotype 1.3 strains

25 **ABSTRACT**

26

27 The porcine reproductive and respiratory syndrome virus (PRRSV) is plaguing porcine
28 production. Previously piglets were immunized with a PRRSV-1 commercial modified live
29 virus vaccine (MLV1), a PRRSV-2 MLV (MLV2) or a Western European strain (Finistere:
30 Fini) to assess and compare the protection brought by these strains upon challenge with
31 virulent Lena strain. Lena viremia was reduced in all the immunized groups with a slightly
32 higher level of protection following immunization with Fini. Using lung samples collected
33 from the same experiment, tissue response to Lena challenge was assessed at the acute and
34 chronic stages of infection. A pre-immunization with any one of the three PRRSV strains
35 globally exacerbated microscopic lung lesions. Ten days post-challenge (DPC), MLV1 group
36 score was higher than unimmunized group score and 42 DPC, MLV2 group score was higher
37 than in unimmunized group. Lowest lung Lena viral loads were measured in Fini group.
38 Using principal component analysis, we showed 10 DPC that the lesion score was positively
39 correlated with chemokine receptors and negatively correlated with viral load. Forty-two
40 DPC, variables for lesion score, IL6, IL8, and CCL20 transcripts were positively correlated
41 together and negatively correlated with CCL28, CXCL6, and CXCR4 transcripts suggesting a
42 role for the latter ones in the tissue recovery process. In conclusions, our study shows a
43 significant impact of the three immunizations on pulmonary tissue with the best protection
44 against Lena challenge conferred by Fini strain. Furthermore, it gives insight into the
45 interactions between vaccine and Fini strains and the lung upon Lena challenge.

46

47 **1. Introduction**

48

49 The porcine reproductive and respiratory syndrome viruses (PRRSV-1 and PRRSV-2)
50 - both members of the *Arteriviridae* family and *Nidovirales* order like equine arteritis virus,
51 simian hemorrhagic fever virus, and lactate dehydrogenase-elevating virus - have a huge
52 impact on the porcine production worldwide (Lunney et al., 2016; Snijder et al., 2013). These
53 viruses are able to counteract the innate immune response of the porcine host and induce a
54 disease characterized by respiratory and genital disorders (for a review see (Du et al., 2017;
55 Lunney et al., 2016)). Historically, two genotypes of PRRSV were identified in the late 1980s:
56 genotype 1 in Europe and genotype 2 in Asia and North America (Keffaber, 1989; Lunney et
57 al., 2016; Wensvoort et al., 1991). These viruses are now classified as two different species.
58 Moreover, different subtypes have been described among PRRSV-1. Subtype 1 strains are
59 mostly low pathogenic strains and circulate primarily in Western Europe even if also present
60 in Asia and North America. Conversely, subtype 3 strains are described as clearly more
61 virulent than subtype 1 strains and have already been identified in Eastern Europe
62 (Weesendorp et al., 2013).

63 Previously, and to prepare for the possible emergence of a subtype 3 strain in Western
64 Europe, piglets were immunized with a PRRSV-1 commercial modified live virus (MLV)
65 vaccine (MLV1), a PRRSV-2 commercial MLV vaccine (MLV2), and a Western European
66 PRRSV strain (Finistere: Fini), to assess and compare the protection brought by these strains
67 upon challenge with the virulent subtype 3 Lena strain four weeks later (Renson et al., 2017a).
68 Basically, it was observed that the levels of Lena viremia were diminished for all the
69 immunized groups and that the immunization with Fini, MLV1, and MLV2 strains shortened
70 the hyperthermia induced by Lena strain (Renson et al., 2017a). Moreover, in the Fini group,
71 they also observed an improvement in growth performance possibly related to a better cell-
72 mediated immune response as suggested by the level of Lena-specific IFN γ -secreting cells.
73 Thus, it appeared that commercial PRRSV-1 and PRRSV-2 MLV vaccines as well as the field

strain Finistere could provide partial clinical and virological protection against a challenge with the virulent Lena strain. However, the study focused primarily on clinical and zootechnical parameters, blood viral load, systemic humoral and cellular responses (ELISPOT using peripheral blood mononuclear cells - PBMC). Because PRRSV multiplies mostly in pulmonary alveolar macrophages and to further our understanding of previous results, we performed the following study. Using lung samples collected from the experiment performed by Renson and collaborators (Renson et al., 2017a), we carried out a molecular and histopathological analysis of the immune response of the lung tissues in the different groups of non-immunized and immunized pigs. This lung tissue analysis completes and broadens the previous report.

2. Materials and methods

2.1. Vaccine and virus strains

Two MLV vaccines were used in the *in vivo* experiment as described by Renson and collaborators (Renson et al., 2017a): the PRRSV-1 Ingelvac PRRSFLEX[®] EU vaccine (Boehringer Ingelheim France, Paris, France, 94881 strain, GenBank accession no. KT988004) (MLV1) and the PRRSV-2 Ingelvac[®] PRRS MLV vaccine (SCS Boehringer Ingelheim Comm, Brussels, Belgium, USA ATCC VR2332 strain, GenBank accession no. EF484033) (MLV2). The PRRSV-1 subtype 1 (1.1) Finistere PRRSV strain (PRRS-FR-2005-29-24-1, GenBank accession no. KY366411) was isolated in France in 2005 from a herd with reproductive failures in sows. In specific pathogen-free (SPF) pigs, Finistere infection induces a mild clinical expression (Rose et al., 2015). The PRRSV-1 subtype 3 (1.3) Lena PRRSV strain (GenBank accession no. JF802085) was kindly provided by Dr. Hans Nauwynck (University of Ghent, Belgium). The Lena strain was isolated in Belarus in 2007 from a herd

with mortality, reproductive failures and respiratory disorders (Karniychuk et al., 2012). The Finistere and the Lena strains were propagated and titrated on pulmonary alveolar macrophages as previously described (Renson et al., 2017a).

2.2. Experimental setting

The experimental setting has been described previously (Renson et al., 2017a). Briefly, 41 four-week-old pure Large White piglets coming from a specific pathogens free nucleus herd were housed in biosecurity level-3 air-filtered animal facilities. The 41 piglets were randomly distributed according to their origin, weight and gender and assigned to five groups housed in separate rooms (Table I). At 6 weeks of age (D-27), 9 piglets were vaccinated intramuscularly with either the MLV1 (minimum dose $10^{4.4}$ TCID50/piglet) or the MLV2 vaccine (minimum dose $10^{4.9}$ TCID50/piglet) (MLV1 and MLV2 group). At the same time, 7 piglets were inoculated intranasally with the PRRSV Finistere strain (5×10^5 50% tissue culture infectious dose (TCID50) per piglet) (Fini group). Intranasal inoculation was performed by direct instillation of the virus suspension in each nostril, using a 5 ml syringe without needle. At 10 weeks of age (D0), all the piglets from the Fini, MLV1, and MLV2 groups were challenged intranasally with the Lena strain (genotype 1.3, 5×10^5 TCID50/piglet). At the same time, 8 non-immunized piglets were also inoculated with the Lena strain (non-immunized, NI group) and 8 non-immunized piglets were mock inoculated (control group).

All the animal experiments were authorized by the French Ministry for Research (authorization no. 2015060113297443_v1) and approved by the national ethics committee (authorization no. 07/07/15-3).

2.3. Sampling/necropsy and histopathological observations

Half of the pigs in each group were euthanized and necropsied at the acute phase of Lena infection (10±1 days post-challenge, DPC) and the remaining pigs at the end of the follow-up (42±1 DPC). Then, pieces from the dorsal diaphragmatic lobe of the lung were collected for each pig and frozen at -80°C or formalin-fixed. Fixed samples were then paraffin-embedded, and sectioned (5 µm thick) before staining with a routine hematoxylin-eosin-saffron (HES) stain (Riva et al., 2014). The microscopic observation was performed by a trained veterinary pathologist who was blind to the experimental setting. A previously published histopathological lung lesion scoring method was used (Jung et al., 2007) and an adapted lesion scoring method including subacute lesions was added. Briefly, in the adapted lesions scoring method the following criteria were scored (i) thickening of alveolar septa (ranging from 0 to 6, where 0 is normal appearance, 1 is mild focal or multifocal, 2 is mild diffuse, 3 is moderate focal or multifocal, 4 is moderate diffuse, 5 is severe focal or multifocal, and 6 is severe diffuse interstitial pneumonia); (ii) accumulation of material in respiratory airways (ranging from 0 to 3, where 0 is normal appearance and 3 is severe); (iii) peribronchiolar or perivascular inflammatory cells cuffing (ranging from 0 to 3, where 0 is normal appearance and 3 is severe); (iv) proliferative subacute bronchiolitis (ranging from 0 to 3, where 0 is normal appearance, 1 is diffuse thickening, 2 is partially occluding and 3 is obliterative); (v) alveolar emphysema (ranging from 0 to 3, where 0 is normal appearance, 1 is focal or multifocal, 2 is focally extensive and 3 is diffuse) and (vi) BALT hyperplasia (ranging from 0 to 3, where 0 is normal appearance and 3 is severe hyperplasia). The total histopathological lung lesion scores ranged from 0 (no abnormalities) to 21 (most severe bronchointerstitial pneumonia) and was expressed as a percentage of the maximal score.

2.4. Immune gene expression analysis and virus detection in the pulmonary tissue using quantitative real-time PCR

149 To detect immuno-related transcripts (cytokines, chemokines, and chemokine
150 receptors) and PRRSV strains, real-time PCR primers were previously developed (Meurens et
151 al., 2009; Nygard et al., 2007) or designed and optimized using Clone Manager 9 (Scientific
152 & Educational Software, Cary, NC, USA) and were purchased from Eurogentec (Liège,
153 Belgium) (see Table II for primer list). Pulmonary tissue samples (two pieces of 1 mm³) were
154 suspended in Trizol reagent (Invitrogen, Cergy Pontoise, France) with ceramic beads
155 (BioSpec Products, OK, USA) and total RNA was isolated using RNeasy Plus Mini Kit
156 (Qiagen, Courtaboeuf, France). The absence of genomic DNA contamination was verified
157 using prepared RNA as a template for quantitative real-time PCR (qPCR). RNA concentration
158 was determined by measuring optical density at 260 nm (OD260) and the RNA quality was
159 assessed by calculating OD260/OD280 ratio and by capillary electrophoresis (Agilent 2100
160 Bioanalyzer, Agilent Technologies Inc., Santa-Clara, USA). cDNA was generated from 100-
161 200 ng of RNA per reaction following a previously described method (Meurens et al., 2007).
162 The generated cDNA was stored at -80 °C. qPCR was performed using cDNA synthesized
163 with Moloney Murine Leukemia Virus reverse transcriptase (Eurogentec). Diluted cDNA
164 (2X) was combined with primer sets (0.2 µL of 10 mM primer stock) and MESA GREEN
165 qPCR MasterMix (Eurogentec) according to the manufacturer's recommendations. The real
166 time PCR was run on CFX96 Bio-Rad Connect (Bio-Rad, Hercules, CA, USA). The cycling
167 conditions were 1 cycle of denaturation 95°C 5 minutes (min), followed by 40 cycles of
168 amplification (95°C/15 seconds (s), 58°C-67°C/40 s depending on the selected gene, see
169 Table II). The fluorescence was automatically measured during the PCR assay. Software CFX
170 manager 3.1 (Bio-Rad) was used to determine the Cycle quantification (*Cq*) in each reaction.
171 A melting curve was elaborated for each primer pair to verify the presence of one gene
172 specific peak. qPCR assays were carried out as previously described using the three most
173 stable reference genes (Delgado-Ortega et al., 2011; Delgado-Ortega et al., 2014; Dobrescu et

al., 2014). Then, qPCR data were expressed as relative values after Genex macro analysis (Bio-Rad) (Vandesompele et al., 2002) using the *Cq* from the samples for the different transcripts.

Regarding the Taqman PCR assay, the mix and the conditions were different. Two μL of 2X diluted cDNA were combined with 5 μL of Takyon No Rox Probe MasterMix dTTP blue 2x (Eurogentec), 0.3 μL of each primer (10 μM), 0.25 μL of probe (10 μM), and water for a final volume of 10 μL . The qPCR conditions were 95°C for 3 min followed by 40 cycles with denaturation at 95°C for 6 s and annealing/elongation for 15 s at 60°C. The Taq-man PCR was also run on a CFX96 Bio-Rad Connect (Bio-Rad).

2.5. Statistical analysis

Comparison of histological lesions, immune responses and Lena strain viral load between experimental groups

Data for the comparison of differences in relative mRNA expression between experimental groups were expressed as relative values. One-Way ANOVA was used to detect differences in relative mRNA expression and composite score between experimental groups. To account for the non-normal distribution of the data, all data were sorted by rank status prior to ANOVA statistical analysis. Tukey's test was used to compare the means of the ranks among the groups. *P*-values less than 0.05 were considered significant. All statistical analyses were done using computer software Prism 6 for Windows (version 6.02; GraphPad Software, San Diego, CA, USA).

Relationships between immunological, histological and virological descriptors

Associations between the relative mRNA expressions of different genes involved in the immune response, the histological Jung score and the Lena strain viral load in the lungs of MLV1, MLV2, Fini and Lena groups were investigated by principal component analysis

(PCA) at 10 DPC (R free software, available from: <http://www.R-project.org>). Two outliers (one pig from MLV1 and one from MLV2 group) with the highest values on the level of expression of chemokines receptors transcripts and having a singular immune response quite different from the other pigs (confirmed by a clustering analysis, data not shown) were discarded from the analysis to better described the associations between the variables.

Due to the absence of detection of Lena strain 42 DPC in all groups, the associations between the set of immune response descriptors and the histological score were assessed by PCA at this time point.

The main objective in PCA is to detect the associations within a set of continuous variables in a small number of dimensions and to provide a low-dimensional (often two-dimensional) graphical representation of these associations (Jolliffe, 2002). Each variable is represented by an arrow inside a correlation circle, the higher the length of the arrow, the higher the variable contribution to the inertia. The angle between arrows indicates the degree of correlation between the variables, the smaller the angle the higher the correlation. An angle of 90° indicates that the two variables are independent and an angle of 180° shows a negative correlation.

3. Results

3.1. Viral replication/load in the lung tissue was lower in the Fini group than in the other immunized groups

At 10 DPC, except in control group, the PRRSV genome was detected without any significant difference between groups ($p > 0.05$). Because PRRSV universal primers could not differentiate the strains used for immunization and challenge, we had to use primers specifically designed for the detection of Lena challenge strain to assess the impact of

immunization on Lena virus load. With these primers, the Lena viral load was found to be significantly lower in the Fini group than in the other immunized and non-immunized control groups ($p < 0.05$, Figure 1). Using PRRSV universal primers, as well as Lena-specific primers, no PRRSV genome was detected for Lena-infected groups 42 DPC (Figure 1).

3.2. Histologic lesions: Pre-immunization with MLV strains showed higher composite scores than with Fini strain

To evaluate the tissular impact of the Lena strain challenge after immunization with another PRRSV strain, lung samples were observed histologically and lesions were scored using a previously published score grid (Jung et al., 2007) adapted to take into account sub-acute lesions including proliferative bronchiolitis and alveolar emphysema (see Table III). Most control animals (7 out of 8) displayed mild interstitial pneumonia (scored 28.7 ± 7.8 % and 27.5 ± 4.3 % 10 and 42 DPC, respectively) mainly represented by a slight thickening of alveolar walls due to infiltration by some inflammatory cells (Figures 2 and 3). These findings indicate a low background of inflammation which may be associated with dust aspiration.

In contrast, all animals (8 out of 8) inoculated with Lena displayed severe and extended lesions of interstitial bronchopneumonia resulting from the thickening of alveolar septa by a mixed population of inflammatory cells and from respiratory airway alterations including the presence of intra-luminal necrotic material, epithelium hyperplasia and peribronchiolar inflammatory cell infiltration.

A pre-immunization with one of the three studied PRRSV strains globally exacerbated microscopic lung lesions: The MLV1-immunized group composite score was higher than the unimmunized group 10 DPC ($p < 0.05$) and the MLV2-immunized group score was higher than the unimmunized group 42 DPC ($p < 0.01$) (Figures 2A and 3). MLV1, MLV2 and Fini-immunized animals displayed prominent alveolar wall thickening and respiratory airway

obstruction by intraluminal materials. In MLV1-immunized animals, we also observed a decreasing trend in the histopathological score between the studied time-points (mean score 70.2 ± 9.7 % and 52.2 ± 12.7 % 10 and 42 DPC, respectively) corresponding mainly to a clearance of the airway debris. Specifically, in MLV1- and MLV2-immunized animals, some foci of necrotic cells admixed with degenerated neutrophils were scattered in lung parenchyma 10 DPC (Figure 2B), and a prominent BALT hyperplasia was identified 42 DPC.

3.3. Analysis of the lung immune response in the different groups of pigs

In order to analyze in more detail, the lung response to Lena strain challenge in pre-immunized pigs, we assessed the expression of various immuno-related transcripts in the lung tissue (see Table II and Figure 4). Regarding transcripts associated with CCR6, IL10, IFN γ , and TNF α no statistically significant differences were observed between groups ($p > 0.05$, data not shown). On the contrary, transcripts associated with chemokines IL8/CXCL8, CCL20, and CXCL6 were more expressed in MLV1, MLV2, and NI groups 10 DPC than in Fini and control groups (Figure 4A). Most of the time, the observed differences were statistically significant ($p < 0.05$). Because we observed an induction of chemokine genes, we next assessed the expression of various CXC chemokine receptors (CXCR1-7) transcripts (Figure 5 and data not shown for CXCR7). Differences in transcript expression were observed. For CXCR2, CXCR5, and CXCR6 transcripts 42 DPC there were trends ($p > 0.05$) for a higher expression in MLV1 and MLV2 groups than in other groups (Figure 5). We then evaluated the transcript expression of the mucosal chemokine CCL28 and its two main receptors, CCR3 and CCR10 (Figure 4B). Again, a trend for a higher expression of some transcripts (CCL28, CCR3, and CCR10) in MLV1 and MLV2 groups 42 DPC than in other groups was observed but the difference was not statistically significant ($p > 0.05$). Moreover,

the highest level of expression of CCL28 transcripts was observed in the MLV1 group 10 DPC (Figure 4B).

Relationships between immunological, histological and virological descriptors in pre-immunized and/or challenged groups

The PCA revealed three groups of associations between variables describing the levels of immunological, histological and virological lung responses 10 DPC (Figure 6A). One group of positively correlated variables (top left corner of the map) comprised the level of expression of chemokines (CCL20, CCL28, CXCL6, IL8/CXCL8) and chemokine receptor transcript CXCR1. A second group of positively correlated variables, located in the right part of the map, was mainly independent from the first group and was related to the level of expression of the transcripts of all other chemokine receptors. To a lesser degree the histological Jung score was positively correlated with this second group of variables. The second group of variables was negatively correlated with the Lena strain viral load in the lung.

Forty-two DPC, the histological score, the levels of expression of IL6, and of chemokine CCL20 were positively correlated (Figure 6B). This group of descriptors was negatively correlated with the level of expression of the CCL28 transcripts. The level of expression of CCL28 transcripts was positively correlated with the level of CXCL6 and CXCR4 transcripts. A third group of positively correlated parameters included the level of expression of transcripts of CXC chemokine receptors 1-6, CCR10 and CCR3.

4. Discussion

In a previous study aimed at assessing and comparing the immune protection conferred by a Western European PRRSV strain (genotype 1.1) and genotypes 1 and 2 commercial MLV (MLV1 & MLV2) vaccines against challenge with the virulent Lena strain, it was

observed that the level of Lena viremia and clinical signs were reduced in all the immunized groups (Renson et al., 2017a). However, compared to vaccine strains, a slightly higher level of protection following immunization with Finistere strain was observed and attributed to a better cellular immune response. Thus, this previous study showed that cross-protection upon challenge with PRRSV Lena strain was possible with two vaccine strains (genotypes 1 and 2, respectively) and one circulating wild-type strain (Finistere) and that the protection was not related with the level of genetic similarity (Renson et al., 2017a). To reach these conclusions the previous study focused on clinical and zootechnical parameters, blood viral load, systemic humoral and cellular responses. However, it did not take into account the lung immune response even though in the first steps of infection PRRSV multiplies mostly in pulmonary macrophages. Thus, we performed this complementary investigation.

In this study, microscopic pulmonary lesions were observed in all groups of animals and histological scores were significantly higher in all infected groups both 10 and 42 DPC than in non-infected. This observation is not surprising considering that, 10 DPC, both blood and lung viral loads remained high in most of the groups except to some extent in Fini and that fever was mostly detected in NI and MLV2 where lesions were well identified (Renson et al., 2017a). Moreover, it is well-known that infections with virulent type 1 subtype 3 Lena strain result in more severe diseases than with other type 1 (Lelystad, Finistere or Belgium A for instance) strains (Renson et al., 2017b; Rose et al., 2015; Weesendorp et al., 2013). Regarding viral loads in the lung, results were similar to what was reported previously with blood viral loads (Renson et al., 2017a) and the lung viral load in the Fini group was significantly lower than in other groups 10 DPC. As previously suggested, the higher protection conferred by Finistere strain immunization compared to other immunization groups (MLV1 and MLV2) could be explained by a better cellular response as deduced from PRRSV-specific IFN γ response detected by ELISPOT. This observation could also be linked

to the attenuation of vaccine strains *versus* non-attenuated wild type Finistere strain and/or route of administration (intranasal *versus* intramuscular) (Wu et al., 1997). Surprisingly, most severe lesions 10 DPC were observed in pigs immunized with MLV1 (70.2 ± 9.8 %) and to a lower extent MLV2 (63 ± 9 %) and foci of necrotic cells admixed with degenerated neutrophils were scattered in the lung parenchyma of the pigs from these groups. However, as previously reported, clinical signs such as rectal temperatures were already reduced 10 DPC in the MLV1 group and 11 DPC in the MLV2 group (Renson et al., 2017a) showing the protective effect of immunization with the two vaccines.

Because of the presence of foci of necrotic cells and degenerated neutrophils in the lung tissues of the MLV1 and MLV2 groups, we then assessed the expression of some transcripts related to inflammation (IL6 and $\text{TNF}\alpha$) and coding for some chemokines mostly involved in neutrophil recruitment (Kulkarni et al., 2017; Zlotnik and Yoshie, 2012). Interestingly, the highest expression of not only CXCL6 and IL8/CXCL8 but also CCL20 transcripts was identified in the MLV1 and MLV2 groups with statistically significant differences. Moreover, using PCA we identified positive correlation between CXCL8/CCL20 and the lesion score 42 DPC, and the induction of CCL20 was the highest in the MLV1 group 10 DPC where the lesion score was also the highest (similar observations were made for the transcripts of CXCR1, receptor of CXCL8). To further verify our hypothesis, we looked at the specific role of the selected chemokines and their receptors. CXCL6, also known as granulocyte chemotactic protein 2 (GCP-2), is produced by macrophages, epithelial and mesenchymal cells during inflammation, is chemoattractant for neutrophilic granulocytes (Proost et al., 1993; Zlotnik and Yoshie, 2012), has antimicrobial properties (Linge et al., 2008), and interacts with two receptors: CXCR1 and CXCR2 (Wuyts et al., 1997). IL8/CXCL8, a CXC chemokine known as neutrophil chemotactic factor, is produced by epithelial cells and macrophages and interacts with CXCR1 and CXCR2 (Harada et al., 1994;

IUIS/WHO Subcommittee on Chemokine Nomenclature, 2003), which are expressed by eosinophils (Petering et al., 1999), neutrophils (Zlotnik and Yoshie, 2012), mast cells (Lippert et al., 1998), and some macrophages (Williams et al., 2000). CCL20, also known as Macrophage Inflammatory Protein-3 (MIP3A), belongs to the CC chemokine family and is strongly chemotactic for lymphocytes while it weakly attracts neutrophils (Hieshima et al., 1997). Thus, our qPCR data support more pronounced inflammatory processes in the MLV1 and MLV2 groups 10 DPC than in the Fini group confirming histo-pathological analyses. We then looked at various chemokine receptor transcripts, especially the ones involved in neutrophil recruitment, to see if chemokine transcript expression had visible consequences on receptor transcript expression. For that purpose, RT-qPCR assays targeting all the CXC chemokine receptors were developed for the pig species. In most cases, no significant differences but trends were observed between groups 42 DPC, probably because of a transient overexpression of receptor transcripts. For instance, it has been shown in mice that IgA antibody-secreting cells express high levels of the receptor CCR9 in lymphoid tissues associated with the gut but down-regulate the expression of the receptor once located in the *lamina propria* (Pabst et al., 2004).

To determine which variables were associated together, we carried out principal component analyses 10 and 42 DPC. Ten DPC, chemokine and CXCR1 variables were all positively correlated probably because the lung was facing Lena assaults and recruited inflammatory cells, particularly in MLV groups. Variables describing other chemokine receptors were all positively correlated together and negatively correlated to Lena lung viral load, illustrating most probably the importance of establishing the cellular arm of the immune response for Lena control. Indeed, CXCR3, CXCR4, CXCR5, CXCR6, and CCR10 are all involved in lymphocyte trafficking (Bonini and Steiner, 1997; Dobner et al., 1992; Groom and Luster, 2011; Loetscher et al., 1997; Moriuchi et al., 1997; Qin et al., 1998; Zlotnik and

Yoshie, 2012). Moreover, the variables describing all these chemokines receptors were positively correlated to Jung score 10 DPC. Forty-two DPC, the situation was different. This is not surprising when we consider that the lung is recovering from PRRSV infection after the clearance of most of the virus particles. At this time, the lesion score and the levels of expression of IL6, IL8, and CCL20 transcripts were all positively correlated while they were negatively correlated with the levels of expression of CCL28, CXCL6, and CXCR4 transcripts. Similarly, according to what was observed 10 DPC, other chemokine receptor variables were all positively correlated. Thus, it appears that the picture is less clear long after challenge than immediately after it. However, a positive correlation between major inflammation actors such as IL6 and IL8/CXCL8 and the lesion score can still be observed. Lena strain induces a stronger inflammatory response than Western European PRRSV strains (Weesendorp et al., 2013) and even if it can contribute to a faster viral clearance it could take a longer time for the tissue to fully recover from the induced lesions. CXCL6, CXCR4, and CCL28 variables were negatively correlated to the first group of variables, which mostly included inflammatory mediators and histological score. Interestingly, an alternative name for CXCL6 is Alveolar Macrophage Chemotactic Factor 2 (Hunninghake et al., 1980; Proost et al., 1993), CXCR4 is associated with lymphocytes and its signaling regulates the expression of CD20 on B cells (Moriuchi et al., 1997; Pavlasova et al., 2016), and CCL28 is a strong chemoattractant of antibody secreting cells (Berri et al., 2008; Feng et al., 2006; Kunkel et al., 2003; Lazarus et al., 2003; Meurens et al., 2006; Wilson and Butcher, 2004). CCL28, also known as *mucosae*-associated epithelial chemokine (MEC), has antimicrobial properties and is expressed by lung mucosa where it drives homing of T and B lymphocytes expressing CCR10 and eosinophils, macrophages, and T lymphocytes expressing CCR3 (Danilova et al., 2015; Humbles et al., 2002; John et al., 2005; Kulkarni et al., 2017; Kunkel et al., 2003; Mantovani et al., 2004; Zlotnik and Yoshie, 2012). Thus, we could hypothesize a role for

these chemokines and chemokine receptor, all involved in macrophage and T cell trafficking, in the recovery process. Regarding potential links between biological variables and immunization groups, we did not observe any correlation, probably because of the low numbers of animals per groups and the relatively small differences between groups.

In conclusions, our study complements and further valorizes valuable samples collected from pigs immunized with two commercial vaccine strains and the Fini wild-type strain before Lena challenge. It shows a significant impact of the three types of immunizations on pulmonary tissue with the best protection against Lena challenge conferred by Fini strain, which induced less the expression of some inflammatory cytokines and chemokines. Furthermore, it gives insight into the interactions between vaccine and Fini strains of PRRSV and the lung upon Lena challenge. The study also provides a more global analysis of the immune lung response following PRRSV challenge giving clues for further studies aiming at better understanding the complex immuno-patho-physiology of PRRSV infections.

Acknowledgements

FM is supported by an establishment grant from the *Région Pays de la Loire* (RFI Food for tomorrow-Cap aliment). This lab work was carried out with the financial support of the regional programme "Food for Tomorrow / Cap Aliment; Research, Education and Innovation in *Pays de la Loire*", which is supported by the French Region Pays de la Loire and the European Regional Development Fund (FEDER). We thank very much Coralie Chatellier and Amandine Bautru for their technical assistance during their training in the lab. Thanks also to Daniel Hogan for his helpful revision of the manuscript regarding English language.

Conflict of interest statement

The authors declare that they have no conflict of interests.

References

- Berri, M., Meurens, F., Lefevre, F., Chevaleyre, C., Zanello, G., Gerdts, V., Salmon, H., 2008. Molecular cloning and functional characterization of porcine CCL28: possible involvement in homing of IgA antibody secreting cells into the mammary gland. *Mol. Immunol.* 45, 271–277. <https://doi.org/10.1016/j.molimm.2007.04.026>
- Bonini, J.A., Steiner, D.F., 1997. Molecular cloning and expression of a novel rat CC-chemokine receptor (rCCR10rR) that binds MCP-1 and MIP-1beta with high affinity. *DNA Cell. Biol.* 16, 1023–1030.
- Danilova, E., Skrindo, I., Gran, E., Hales, B.J., Smith, W.A., Jahnsen, J., Johansen, F.E., Jahnsen, F.L., Baekkevold, E.S., 2015. A role for CCL28-CCR3 in T-cell homing to the human upper airway mucosa. *Mucosal Immunol.* 8, 107–14. <https://doi.org/10.1038/mi.2014.46>
- Delgado-Ortega, M., Melo, S., Meurens, F., 2011. Expression of SOCS1-7 and CIS mRNA in porcine tissues. *Vet Immunol Immunopathol* 144, 493–498. <https://doi.org/10.1016/j.vetimm.2011.08.002>
- Delgado-Ortega, M., Melo, S., Punyadarsaniya, D., Ramé, C., Olivier, M., Soubieux, D., Marc, D., Simon, G., Herrler, G., Berri, M., Dupont, J., Meurens, F., 2014. Innate immune response to a H3N2 subtype swine influenza virus in newborn porcine trachea cells, alveolar macrophages, and precision-cut lung slices. *Vet. Res.* 45, 42. <https://doi.org/10.1186/1297-9716-45-42>

448 Dobner, T., Wolf, I., Emrich, T., Lipp, M., 1992. Differentiation-specific expression of a
 449 novel G protein-coupled receptor from Burkitt's lymphoma. *Eur. J. Immunol.* 22, 2795–
 450 2799. <https://doi.org/10.1002/eji.1830221107>
 451 Dobrescu, I., Levast, B., Lai, K., Delgado-Ortega, M., Walker, S., Banman, S., Townsend, H.,
 452 Simon, G., Zhou, Y., Gerdts, V., Meurens, F., 2014. *In vitro* and *ex vivo* analyses of co-
 453 infections with swine influenza and porcine reproductive and respiratory syndrome
 454 viruses. *Vet. Microbiol.* 169, 18–32. <https://doi.org/10.1016/j.vetmic.2013.11.037>
 455 Du, T., Nan, Y., Xiao, S., Zhao, Q., Zhou, E.-M., 2017. Antiviral Strategies against PRRSV
 456 Infection. *Trends Microbiol.* 25, 968–979. <https://doi.org/10.1016/j.tim.2017.06.001>
 457 Feng, N., Jaimes, M.C., Lazarus, N.H., Monak, D., Zhang, C., Butcher, E.C., Greenberg,
 458 H.B., 2006. Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA+
 459 plasmablast recruitment to the intestinal *lamina propria* after rotavirus infection. *J.*
 460 *Immunol.* 176, 5749–5759.
 461 Groom, J.R., Luster, A.D., 2011. CXCR3 in T cell function. *Exp. Cell Res.* 317, 620–631.
 462 <https://doi.org/10.1016/j.yexcr.2010.12.017>
 463 Harada, A., Sekido, N., Akahoshi, T., Wada, T., Mukaida, N., Matsushima, K., 1994.
 464 Essential involvement of interleukin-8 (IL-8) in acute inflammation. *J. Leukoc. Biol.* 56,
 465 559–64.
 466 Hieshima, K., Imai, T., Opdenakker, G., Van Damme, J., Kusuda, J., Tei, H., Sakaki, Y.,
 467 Takatsuki, K., Miura, R., Yoshie, O., Nomiya, H., 1997. Molecular cloning of a novel
 468 human CC chemokine liver and activation-regulated chemokine (LARC) expressed in
 469 liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. *J.*
 470 *Biol. Chem.* 272, 5846–53.
 471 Humbles, A.A., Lu, B., Friend, D.S., Okinaga, S., Lora, J., Al-garawi, A., Martin, T.R.,
 472 Gerard, N.P., Gerard, C., 2002. The murine CCR3 receptor regulates both the role of

eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. *Proc. Natl. Acad. Sci.* 99, 1479–1484. <https://doi.org/10.1073/pnas.261462598>

Hunninghake, G.W., Gadek, J.E., Fales, H.M., Crystal, R.G., 1980. Human Alveolar Macrophage-derived Chemotactic Factor for Neutrophils. *J. Clin. Invest.* 66, 473–483. <https://doi.org/10.1172/JCI109878>

IUIS/WHO Subcommittee on Chemokine Nomenclature, 2003. Chemokine/chemokine receptor nomenclature. *Cytokine* 21, 48–9.

John, A.E., Thomas, M.S., Berlin, A.A., Lukacs, N.W., 2005. Temporal production of CCL28 corresponds to eosinophil accumulation and airway hyperreactivity in allergic airway inflammation. *Am. J. Pathol.* 166, 345–53. [https://doi.org/10.1016/S0002-9440\(10\)62258-4](https://doi.org/10.1016/S0002-9440(10)62258-4)

Joliffe, I., 2002. Principal component analysis, 2nd Editio. ed. Springer New York, New York, USA.

Jung, K., Alekseev, K.P., Zhang, X., Cheon, D.S., Vlasova, A.N., Saif, L.J., 2007. Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus. *J. Virol.* 81, 13681–13693.

Karniyuchuk, U.U., Saha, D., Vanhee, M., Geldhof, M., Cornillie, P., Caij, A.B., De Regge, N., Nauwynck, H.J., 2012. Impact of a novel inactivated PRRS virus vaccine on virus replication and virus-induced pathology in fetal implantation sites and fetuses upon challenge. *Theriogenology* 78, 1527–37. <https://doi.org/10.1016/j.theriogenology.2012.06.015>

Keffaber, K.K., 1989. Reproductive failure of unknown etiology. *Am. Assoc. Swine Pr. Newsl.* 1, 1–9.

498 Kulkarni, N., Pathak, M., Lal, G., 2017. Role of chemokine receptors and intestinal epithelial
 499 cells in the mucosal inflammation and tolerance. *J. Leukoc. Biol.* 101, 377–394.
 500 <https://doi.org/10.1189/jlb.1RU0716-327R>

501 Kunkel, E.J., Kim, C.H., Lazarus, N.H., Viera, M.A., Soler, D., Bowman, E.P., Butcher,
 502 E.C., 2003. CCR10 expression is a common feature of circulating and mucosal epithelial
 503 tissue IgA Ab-secreting cells. *J. Clin. Invest.* 111, 1001–1010.

504 Lazarus, N.H., Kunkel, E.J., Johnston, B., Wilson, E., Youngman, K.R., Butcher, E.C., 2003.
 505 A common mucosal chemokine (*mucosae*-associated epithelial chemokine/CCL28)
 506 selectively attracts IgA plasmablasts. *J. Immunol.* 170, 3799–3805.

507 Linge, H.M., Collin, M., Nordenfelt, P., Morgelin, M., Malmsten, M., Egesten, A., 2008. The
 508 Human CXC Chemokine Granulocyte Chemotactic Protein 2 (GCP-2)/CXCL6 Possesses
 509 Membrane-Disrupting Properties and Is Antibacterial. *Antimicrob. Agents Chemother.*
 510 52, 2599–2607. <https://doi.org/10.1128/AAC.00028-08>

511 Lippert, U., Artuc, M., Grützkau, A., Möller, A., Kenderessy-Szabo, A., Schadendorf, D.,
 512 Norgauer, J., Hartmann, K., Schweitzer-Stenner, R., Zuberbier, T., Henz, B.M., Krüger-
 513 Krasagakes, S., 1998. Expression and functional activity of the IL-8 receptor type
 514 CXCR1 and CXCR2 on human mast cells. *J. Immunol.* 161, 2600–8.

515 Loetscher, M., Amara, A., Oberlin, E., Brass, N., Legler, D., Loetscher, P., D'Apuzzo, M.,
 516 Meese, E., Rousset, D., Virelizier, J.L., Baggiolini, M., Arenzana-Seisdedos, F., Moser,
 517 B., 1997. TYMSTR, a putative chemokine receptor selectively expressed in activated T
 518 cells, exhibits HIV-1 coreceptor function. *Curr. Biol.* 7, 652–60.

519 Lunney, J.K., Fang, Y., Ladinig, A., Chen, N., Li, Y., Rowland, B., Renukaradhya, G.J., 2016.
 520 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV): Pathogenesis and
 521 Interaction with the Immune System. *Annu. Rev. Anim. Biosci.* 4, 129–154.
 522 <https://doi.org/10.1146/annurev-animal-022114-111025>

523 Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., 2004. The
524 chemokine system in diverse forms of macrophage activation and polarization. Trends
525 Immunol. 25, 677–686. <https://doi.org/10.1016/j.it.2004.09.015>

526 Meurens, F., Berri, M., Auray, G., Melo, S., Levast, B., Virlogeux-Payant, I., Chevaleyre, C.,
527 Gerdt, V., Salmon, H., 2009. Early immune response following *Salmonella enterica*
528 subspecies enterica serovar Typhimurium infection in porcine jejunal gut loops. Vet.
529 Res. 40. <https://doi.org/10.1051/vetres:2008043>

530 Meurens, F., Berri, M., Siggers, R.H.H., Willing, B.P.P., Salmon, H., Van Kessel, A.G.G.,
531 Gerdt, V., 2007. Commensal bacteria and expression of two major intestinal
532 chemokines, TECK/CCL25 and MEC/CCL28, and their receptors. PLoS One 2, e677.
533 <https://doi.org/10.1371/journal.pone.0000677>

534 Meurens, F., Berri, M., Whale, J., Dybvig, T., Strom, S., Thompson, D., Brownlie, R.,
535 Townsend, H.G.G., Salmon, H., Gerdt, V., 2006. Expression of TECK/CCL25 and
536 MEC/CCL28 chemokines and their respective receptors CCR9 and CCR10 in porcine
537 mucosal tissues. Vet. Immunol. Immunopathol. 113.
538 <https://doi.org/10.1016/j.vetimm.2006.05.014>

539 Moriuchi, M., Moriuchi, H., Turner, W., Fauci, A.S., 1997. Cloning and analysis of the
540 promoter region of CXCR4, a coreceptor for HIV-1 entry. J. Immunol. 159, 4322–9.

541 Nygard, A.B., Jorgensen, C.B., Cirera, S., Fredholm, M., 2007. Selection of reference genes
542 for gene expression studies in pig tissues using SYBR green qPCR. BMC Mol. Biol. 8,
543 67.

544 Pabst, O., Ohl, L., Wendland, M., Wurbel, M.A., Kremmer, E., Malissen, B., Forster, R.,
545 2004. Chemokine receptor CCR9 contributes to the localization of plasma cells to the
546 small intestine. J. Exp. Med. 199, 411–416.

547 Pavlasova, G., Borsky, M., Seda, V., Cerna, K., Osickova, J., Doubek, M., Mayer, J.,

548 Calogero, R., Trbusek, M., Pospisilova, S., Davids, M.S., Kipps, T.J., Brown, J.R., Mraz,
 549 M., 2016. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the
 550 CXCR4/SDF-1 axis. *Blood* 128, 1609–1613. [https://doi.org/10.1182/blood-2016-04-](https://doi.org/10.1182/blood-2016-04-709519)
 551 709519

552 Petering, H., Götze, O., Kimmig, D., Smolarski, R., Kapp, A., Elsner, J., 1999. The biologic
 553 role of interleukin-8: functional analysis and expression of CXCR1 and CXCR2 on
 554 human eosinophils. *Blood* 93, 694–702.

555 Proost, P., Wuyts, A., Conings, R., Lenaerts, J.P., Billiau, A., Opdenakker, G., Van Damme,
 556 J., 1993. Human and bovine granulocyte chemotactic protein-2: complete amino acid
 557 sequence and functional characterization as chemokines. *Biochemistry* 32, 10170–7.

558 Qin, S., Rottman, J.B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A.E.,
 559 Moser, B., Mackay, C.R., 1998. The chemokine receptors CXCR3 and CCR5 mark
 560 subsets of T cells associated with certain inflammatory reactions. *J. Clin. Invest.* 101,
 561 746–54. <https://doi.org/10.1172/JCI1422>

562 Renson, P., Fablet, C., Le Dimna, M., Mahé, S., Touzain, F., Blanchard, Y., Paboeuf, F.,
 563 Rose, N., Bourry, O., 2017a. Preparation for emergence of an Eastern European porcine
 564 reproductive and respiratory syndrome virus (PRRSV) strain in Western Europe:
 565 Immunization with modified live virus vaccines or a field strain confers partial
 566 protection. *Vet. Microbiol.* 204, 133–140. <https://doi.org/10.1016/j.vetmic.2017.04.021>

567 Renson, P., Rose, N., Le Dimna, M., Mahé, S., Keranflec'h, A., Paboeuf, F., Belloc, C., Le
 568 Potier, M.-F., Bourry, O., 2017b. Dynamic changes in bronchoalveolar macrophages and
 569 cytokines during infection of pigs with a highly or low pathogenic genotype 1 PRRSV
 570 strain. *Vet. Res.* 48, 15. <https://doi.org/10.1186/s13567-017-0420-y>

571 Riva, M., Manzoni, M., Isimbaldi, G., Cesana, G., Pagni, F., 2014. Histochemistry: historical
 572 development and current use in pathology. *Biotech. Histochem.* 89, 81–90.

573 <https://doi.org/10.3109/10520295.2013.822559>

574 Rose, N., Renson, P., Andraud, M., Paboeuf, F., Le Potier, M.F., Bourry, O., 2015. Porcine
 575 reproductive and respiratory syndrome virus (PRRSv) modified-live vaccine reduces
 576 virus transmission in experimental conditions. *Vaccine* 33, 2493–9.
 577 <https://doi.org/10.1016/j.vaccine.2015.03.040>

578 Snijder, E.J., Kikkert, M., Fang, Y., 2013. Arterivirus molecular biology and pathogenesis. *J.*
 579 *Gen. Virol.* 94, 2141–2163. <https://doi.org/10.1099/vir.0.056341-0>

580 Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman,
 581 F., 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric
 582 averaging of multiple internal control genes. *Genome Biol* 3, RESEARCH0034.

583 Weesendorp, E., Morgan, S., Stockhofe-Zurwieden, N., Graaf, D.J.P.-D., Graham, S.P.,
 584 Rebel, J.M.J., 2013. Comparative analysis of immune responses following experimental
 585 infection of pigs with European porcine reproductive and respiratory syndrome virus
 586 strains of differing virulence. *Vet. Microbiol.* 163, 1–12.
 587 <https://doi.org/10.1016/j.vetmic.2012.09.013>

588 Wensvoort, G., Terpstra, C., Pol, J.M., ter Laak, E.A., Bloemraad, M., de Kluyver, E.P.,
 589 Kragten, C., van Buiten, L., den Besten, A., Wagenaar, F., al., et, 1991. Mystery swine
 590 disease in The Netherlands: the isolation of Lelystad virus. *Vet. Q* 13, 121–130.

591 Williams, E.J., Haque, S., Banks, C., Johnson, P., Sarsfield, P., Sheron, N., 2000. Distribution
 592 of the interleukin-8 receptors, CXCR1 and CXCR2, in inflamed gut tissue. *J. Pathol.*
 593 192, 533–539. [https://doi.org/10.1002/1096-9896\(2000\)9999:9999<::AID-](https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH732>3.0.CO;2-X)
 594 [PATH732>3.0.CO;2-X](https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH732>3.0.CO;2-X)

595 Wilson, E., Butcher, E.C., 2004. CCL28 controls immunoglobulin (Ig)A plasma cell
 596 accumulation in the lactating mammary gland and IgA antibody transfer to the neonate.
 597 *J. Exp. Med.* 200, 805–809.

Wu, H.Y., Nguyen, H.H., Russell, M.W., 1997. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. *Scand. J. Immunol.* 46, 506–513.

Wuyts, A., Van Osselaer, N., Haelens, A., Samson, I., Herdewijn, P., Ben-Baruch, A., Oppenheim, J.J., Proost, P., Van Damme, J., 1997. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and *in vivo* inflammatory properties. *Biochemistry* 36, 2716–23.
<https://doi.org/10.1021/bi961999z>

Zlotnik, A., Yoshie, O., 2012. The Chemokine Superfamily Revisited. *Immunity* 36, 705–716.
<https://doi.org/10.1016/J.IMMUNI.2012.05.008>

Figure captions

Figure 1: Viral replication - Relative quantification of viral load in lung tissue 10 or 42 days post-challenge (DPC). In each group n=3 to 5 (median is indicated by the small bar). Dot plots within each graph with no common superscripts are significantly different ($p < 0.05$). MLV1 group: pigs immunized with the MLV1 vaccine; MLV2 group: pigs immunized with the MLV2 vaccine; Fini group: pigs immunized with the Finistere strain of PRRSV; NI group: non-immunized pigs.

Figure 2: (A) Lung histopathology - Representative pictures of the histopathological lesions observed in control, MLV1, MLV2 or Finistere PRRSV (Fini) strain-inoculated pigs before Lena strain challenge or Lena strain alone (NI), 10 (upper panel) and 42 (lower panel) days post-challenge (DPC). Compared to control animals, lungs of PRRSV inoculated/immunized and challenged animals displayed severe bronchopneumonia characterized by alveolar wall thickening by inflammatory cells, presence of necrotic and cellular debris in respiratory

airways ((open) arrowhead) and peri-bronchiolar and peri-vascular cuffing by inflammatory cells (arrow). Note, 42 DPC, hyperplasia of Bronchi-Associated Lymphoid Tissues (*). Hematoxylin-eosin-saffron stain, bar = 100 μ m. **(B) High magnification of lung parenchyma.** Compared to control animals, all Lena-infected animals displayed thickening of alveolar septa by some inflammatory cells, mainly mononucleated ones (black arrowhead). 10 days post-challenge (DPC), in MLV1 and MLV2 groups, some neutrophils (arrow) were regularly observed around small foci of necrotic debris accumulation (open arrowhead). Meanwhile, these foci and neutrophils were almost absent in Fini and NI animals. Hematoxylin-eosin-saffron stain, bar = 10 μ m.

Figure 3: Composite scores in the different groups 10 and 42 DPC. In each group n=3 to 5 (median is indicated by the small bar). Dot plots within each graph with no common superscripts are significantly different ($p < 0.05$). MLV1 group: pigs immunized with the MLV1 vaccine; MLV2 group: pigs immunized with the MLV2 vaccine; Fini group: pigs immunized with the Finistere strain of PRRSV; NI group: non-immunized pigs.

Figure 4: (A) Innate immune response - Relative expression of transcripts in lung tissues 10 or 42 days post Lena challenge (DPC). **(B) CCL28 chemokine and its receptors** - Relative expression of transcripts in lung tissues 10 or 42 days post-challenge (DPC). In each group n=3 to 5 (median is indicated by the small bar). Dot plots within each graph with no common superscripts are significantly different ($p < 0.05$). MLV1 group: pigs immunized with the MLV1 vaccine; MLV2 group: pigs immunized with the MLV2 vaccine; Fini group: pigs immunized with the Finistere strain of PRRSV; NI group: non-immunized pigs.

Figure 5: CXCR chemokines - Relative expression of transcripts in lung tissues 10 or 42

days post-challenge (DPC). In each group n=3 to 5 (median is indicated by the small bar). Dot plots within each graph with no common superscripts are significantly different ($p < 0.05$). MLV1 group: pigs immunized with the MLV1 vaccine; MLV2 group: pigs immunized with the MLV2 vaccine; Fini group: pigs immunized with the Finistere strain of PRRSV; NI group: non-immunized pigs.

Figure 6: Results of the principal component analysis describing, 10 days (A) and 42 days (B) after a Lena strain challenge, the associations between viral, histologic and immune descriptors of pigs, pre-immunized or not, before the Lena strain challenge (16 pigs in A and 18 in B) - IL6_10: Level of expression of the IL6; IL8_10: Level of expression of the chemokine ligand 8; CCL20_10: Level of expression of the chemokine ligand 20; CXCL6_10: Level of expression of the chemokine ligand 6; CXCR1_10: Level of expression of transcript of the chemokine receptor 1; CXCR2_10: Level of expression of transcript of the chemokine receptor 2; CXCR3_10: Level of expression of transcript of the chemokine receptor 3; CXCR4_10: Level of expression of transcript of the chemokine receptor 4; CXCR5_10: Level of expression of transcript of the chemokine receptor 5; CXCR6_10: Level of expression of transcript of the chemokine receptor 6; CCL28_10: CXCL6_10: Level of expression of the chemokine ligand 28; CCR3_10: Level of expression of transcript of the chemokine receptor 3; CCR10_10: Level of expression of transcript of the chemokine receptor 10 ; RTPCR_Lena_10: Viral Lena strain load in the lung ; IL6_42: Level of expression of the IL6; IL8_42: Level of expression of the chemokine ligand 8; CCL20_42: Level of expression of the chemokine ligand 20; CXCL6_42: Level of expression of the chemokine ligand 6; CXCR1_42: Level of expression of transcript of the chemokine receptor 1; CXCR2_42: Level of expression of transcript of the chemokine receptor 2; CXCR3_42: Level of expression of transcript of the chemokine receptor 3; CXCR4_42: Level of

673 expression of transcript of the chemokine receptor4; CXCR5_42: Level of expression of
674 transcript of the chemokine receptor 5; CXCR6_42: Level of expression of transcript of the
675 chemokine receptor 6; CCL28_42: CXCL6_42: Level of expression of the chemokine ligand
676 28; CCR3_42: Level of expression of transcript of the chemokine receptor 3; CCR10_42:
677 Level of expression of transcript of the chemokine receptor 10 ; Jung score: Histologic Jung
678 score.

PRRSV replication






Figure 1








Figure 3

A**B****Figure 4**




Figure 5





Figure 6

Table I: Experimental design

<i>Groups</i>	<i>Immunization (D -27)</i>	<i>Challenge (D0)</i>	<i>Number of pigs necropsied 10 DPC</i>	<i>Number of pigs necropsied 42 DPC</i>
Control	/	/	4	4
MLV1 <i>Genotype 1.1</i>	Ingelvac PRRSVFLEX EU, IM	Lena, IN	4	5
MLV2 <i>Genotype 2</i>	Ingelvac PRRSV MLV, IM	Lena, IN	4	5
Finistere (Fini) <i>Genotype 1.1</i>	Finistere strain, IN	Lena, IN	3	4
Lena (NI) <i>Genotype 1.3</i>	/	Lena, IN	4	4

IN: intranasal ; IM: intramuscular ; DPC: day post challenge; NI: non-immunized

Table II: List of primers used in the study

<i>Primer abbreviation and full name</i>	<i>Primer sequences: sense (S) & anti-sense (AS)</i>	<i>Amplicon size (bp)</i>	<i>Annealing temperature (°C)</i>	<i>Efficiency (%)</i>	<i>Accession number or reference</i>
1) PRRSV					
PRRSV Universal	(S) ATGGCCAGCCAGTCAATCAG (AS) GGAACGTTCAAGTCCGGTGA	nd	60	95	NC_001961.1 JF802085.1 KJ127878.1 AY366525.1
PRRSV Lena	(S) AGAACCAGCGCCAATTCAGA (AS) TCTTTTTCGCTGTCTCC (P) (6FAM)- AAACACAGCTCCAATGGGGAATGGC-(TAM)	135	60	97	Renson <i>et al.</i> , 2017b
2) REFERENCE GENES					
B2MI <i>Beta-2-microglobulin</i>	(S) CAAGATAGTTAAGTGGGATCGAGAC (AS) TGGTAACATCAATACGATTTCTGA	161	58	101	Nygard <i>et al.</i> , 2007
HPRT1 <i>Hypoxanthine phosphoribosyltransferase 1</i>	(S) GGACTTGAATCATGTTTGTG (AS) CAGATGTTTCCAACTCAAC	91	60	99	Nygard <i>et al.</i> , 2007
RPL19 <i>Ribosomal protein L19</i>	(S) AACTCCCGTCAGCAGATCC (AS) AGTACCCTTCGCTTACCG	147	60	96	Meurens <i>et al.</i> , 2009
3) INTERFERON AND CYTOKINES					
IFNγ <i>Interferon gamma (Type II)</i>	(S) GCTCTGGGAACTGAATGAC (AS) TCTCTGGCCTTGAACATAG	167	60	97	Meurens <i>et al.</i> , 2009
IL6 <i>Interleukin 6</i>	(S) ATCAGGAGACCTGCTTGATG (AS) TGGTGGCTTTGTCTGGATTG	177	60	106	Meurens <i>et al.</i> , 2009
IL10 <i>Interleukin 10</i>	(S) ACCAGATGGGCGACTTGTGTG (AS) TCTCTGCCTTCGGCATTACG	123	65	110	Meurens <i>et al.</i> , 2009
TNFα <i>Tumor Necrosis Factor alpha</i>	(S) CCAATGGCAGAGTGGGTATG (AS) TGAAGAGGACCTGGGAGTAG	116	60	94	Meurens <i>et al.</i> , 2009
4) CHEMOKINES					
CCL20 <i>Chemokine (C-C motif) ligand 20</i>	(S) GCTCCTGGCTGCTTTGATGTC (AS) CATTGGCGAGCTGCTGTGTG	146	65	90	Meurens <i>et al.</i> , 2009
CCL28 <i>Chemokine (C-C motif) ligand 28</i>	(S) GCTGCTGCACTGAGGTTTC (AS) TGAGGGCTGACACAGATTG	144	63	106	Meurens <i>et al.</i> , 2009
CXCL6 <i>Chemokine (C-X-C motif) ligand 6</i>	(S) TTGCCAGCGCTAGTCTCTATC (AS) TTCAGGGTGGCTATCACTTC	166	62	107	NM_213876
CXCL8/IL8 <i>Chemokine (C-X-C motif) ligand 8</i>	(S) TCCTGCTTTCTGCAGCTCTC (AS) GGGTGAAAAGGTGTGGAATG	100	62	92	Meurens <i>et al.</i> , 2009
5) CHEMOKINE RECEPTORS					
CCR3 <i>Chemokine (CC motif) receptor 3</i>	(S) TCCTATTACGCTGCCATTC (AS) TGCAGACCACATCTCCAAAC	303	64	100	XM_013981570
CCR6 <i>Chemokine (CC motif) receptor 6</i>	(S) GGCAGAAAGTTCCGGAGCTAC (AS) TGGTGAAAGGAGGACGGATTG	165	63	92	XM_021086056
CCR10 <i>Chemokine (CC motif) receptor 10</i>	(S) TCCTGCTTTCTGCAGCTCTC (AS) GGGTGAAAAGGTGTGGAATG	444	60.5	94	DQ157761
CXCR1 <i>Chemokine (CXC motif) receptor 1</i>	(S) ATGGCTGGTGATTTCAGATCG (AS) ACCAGGGCATAGATGACAAC	185	64	109	XM_003133655.4
CXCR2 <i>Chemokine (CXC motif) receptor 2</i>	(S) GATATCTCGGGTTTCCAACG (AS) GGGCAGAGTCTGGTAGAATC	176	64	97	XM_021075282.1
CXCR3 <i>Chemokine (CXC motif) receptor 3</i>	(S) TATCGGCCACCCCTGATGAG (AS) GGATGCGGGCGTAGCAATAG	147	62	98	XM_003135179
CXCR4 <i>Chemokine (CXC motif) receptor 4</i>	(S) CCTGGCCTTCATCAGTCTGG (AS) GCGGTCACAGATGTACCTCC	187	64	96	DQ124104
CXCR5 <i>Chemokine (CXC motif) receptor 5</i>	(S) CTCTGCAAGACTGTGATAGC (AS) TGGTTGCACAGGTGATATGG	157	60	100	XM_003129915
CXCR6 <i>Chemokine (CXC motif) receptor 6</i>	(S) GCTTCATTGCAGTGGTTAGG (AS) ATGATCTGTGGCAAGGAGAC	124	58.5	109	NM_001001623
CXCR7 <i>Chemokine (CXC motif) receptor 7</i>	(S) CAGCCTCGTGACGATAACC (AS) TGGACGTGTGGGCGAAGTAG	155	65	104	XM_003133759

Group	Alveolar septa thickening	Airway material	Peri-bronchiolar and -vascular inflammation	Alveolar emphysema	Proliferative bronchitis	BALT	Jung score	Composite score
Control 10 DPC	3	1	1	1	0	0	42%	29%
Control 10 DPC	0	1	2	1	0	0	25%	19%
Control 10 DPC	3	1	0	2	0	0	33%	29%
Control 10 DPC	3	2	2	1	0	0	58%	38%
Control 42 DPC	2	0	2	1	0	0	33%	24%
Control 42 DPC	1	1	1	2	0	0	25%	24%
Control 42 DPC	1	2	1	2	0	0	33%	29%
Control 42 DPC	2	1	2	2	0	0	42%	33%
MLV1 10 DPC	6	3	3	3	1	0	100%	76%
MLV1 10 DPC	6	3	3	3	2	0	100%	81%
MLV1 10 DPC	5	2	3	3	0	0	83%	62%
MLV1 10 DPC	5	2	2	3	0	1	75%	62%
MLV1 42 DPC	5	1	1	2	2	1	58%	57%
MLV1 42 DPC	4	2	3	2	1	1	75%	62%
MLV1 42 DPC	5	1	2	2	0	1	67%	52%
MLV1 42 DPC	3	1	1	1	0	1	42%	33%
MLV1 42 DPC	5	1	1	2	3	0	58%	57%
MLV2 10 DPC	4	2	3	1	2	1	75%	62%
MLV2 10 DPC	6	1	3	2	0	0	83%	57%
MLV2 10 DPC	5	2	3	2	0	0	83%	57%
MLV2 10 DPC	6	3	3	2	2	0	100%	76%
MLV2 42 DPC	5	3	2	3	2	0	83%	71%
MLV2 42 DPC	4	3	3	3	2	2	83%	81%
MLV2 42 DPC	4	2	2	3	2	2	67%	71%
MLV2 42 DPC	5	2	2	3	1	1	75%	67%
MLV2 42 DPC	5	1	1	2	1	1	58%	52%
Fini 10 DPC	5	1	2	3	0	0	67%	52%
Fini 10 DPC	5	0	2	3	0	0	58%	48%
Fini 10 DPC	6	2	2	3	1	0	83%	67%
Fini 10 DPC	4	2	2	3	1	0	67%	57%
Fini 42 DPC	6	3	3	3	0	0	100%	71%
Fini 42 DPC	5	3	3	3	0	0	92%	67%
Fini 42 DPC	6	2	3	3	0	0	92%	67%
NI 10 DPC	3	2	3	2	0	0	67%	48%
NI 10 DPC	3	2	3	3	0	0	67%	52%
NI 10 DPC	2	2	3	2	0	0	58%	43%
NI 10 DPC	5	3	2	2	0	0	83%	57%
NI 42 DPC	4	1	2	3	0	0	58%	48%
NI 42 DPC	4	1	2	2	0	0	58%	43%
NI 42 DPC	5	1	2	2	0	0	67%	48%
NI 42 DPC	4	1	2	2	0	0	58%	43%